Merck & Co. Inc. (MRK) said Thursday the US Food and Drug Administration has approved its Janumet XR tablets as a new treatment for type 2 diabetes. The drug will be available in U.S. pharmacies in the next several weeks.
Janumet XR combines sitagliptin, which is the active component of Merck's blockbuster drug Januvia (sitagliptin), with extended-release metformin.
In Merck's fourth quarter 2011, Januvia sales rose 42 percent from last year to $960 million, while Janumet sales improved 34 percent to $386 million.
Janumet XR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes when treatment with both sitagliptin and extended-release metformin is appropriate.
The drug is not recommended for use in type 1 diabetes or for the treatment of diabetic ketoacidosis. It has not been studied in patients with a history of pancreatitis.
"Janumet XR is a new treatment that adds once-daily convenience to the powerful efficacy of Janumet for patients with type 2 diabetes," said Barry Goldstein, vice president, Diabetes and Endocrinology, Merck.
"This is important because many patients with type 2 diabetes require treatment with multiple drugs to maintain blood sugar control, and Janumet XR is a new option to help more patients get to their glucose goals."
Janumet XR targets three key defects of diabetes: insulin deficiency from pancreatic beta cells, insulin resistance, and overproduction of glucose by the liver.
The labeling for Janumet XR contains a boxed warning for lactic acidosis, a rare, but serious complication attributed to metformin accumulation.
The drug is also contraindicated in patients with renal impairment; hypersensitivity to metformin HCl; acute metabolic acidosis; history of a serious hypersensitivity reaction to Janumet XR or sitagliptin.
The approval for Janumet XR was based upon a double-blind, placebo-controlled study of 1,091 patients who did not respond adequately to diet and exercise. Results showed that co-administration of metformin immediate-release and sitagliptin twice-daily resulted in a reduction of blood sugar relative to placebo.
The most common adverse reactions reported with sitagliptin and metformin immediate-release as initial therapy compared to metformin immediate-release alone were diarrhea, upper respiratory infection and headache.
Janumet XR is priced comparable to both Januvia and Janumet ((sitagliptin/metformin hydrochloride), on a per-daily-dose basis, Merck said in a statement.
MRK is trading on the NYSE at $38.50, down $0.13 or 0.34%, on a volume of 16.7 million shares.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.